A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.
Oral valproic acid (VPA), which is a histone deacetylase inhibitor, was used in a phase II trial to treat patients with castration-resistant prostate cancer (CRPC). Ten patients with CRPC were treated with oral VPA. Oral VPA was not well tolerated in this patient population at a dose targeted to a serum level less than 50 microg/L. The main toxicities were grades 1 and 2 neurologic events and grades 1 and 2 fatigue that caused interruption in the administration of oral VPA and dose delays. Two (20%) of 10 patients had prostate-specific antigen (PSA) responses, and one response was durable. Intensive biomarker collections (weekly) revealed that PSA levels were inversely correlated with total VPA levels. Histone acetylation could not be consistently observed in peripheral lymphocytes using oral VPA. Oral VPA can be administered to CRPC patients with resultant PSA responses. However, oral VPA cannot be administered reliably to achieve consistent levels or duration to be useful in the treatment of CRPC patients. It is unlikely that PSA responses from oral VPA are related to histone deacetylase inhibition. Development of oral VPA in prostate cancers is not recommended using an oral formulation. An intensive biomarker strategy is useful to develop clinical hypotheses in patients with CRPCs in small numbers of patients.
Sharma
Sunil
S
Nevada Cancer Institute, 1 Breakthrough Way, Las Vegas, NV 89135, USA.
Symanowski
James
J
Wong
Bryan
B
Dino
Pamela
P
Manno
Phillip
P
Vogelzang
Nicholas
N
J Clin Oncol. 2008 Jan 10;26(2):242-5
18182665
Cancer Res. 1992 Jan 1;52(1):168-72
1727377
J Clin Oncol. 2005 Jun 10;23(17):3923-31
15897550
Rev Urol. 2007;9 Suppl 2:S3-S12
17554403
J Antibiot (Tokyo). 1990 Sep;43(9):1101-6
2211374
Cancer Res. 2004 Feb 1;64(3):1079-86
14871841
N Engl J Med. 2004 Oct 7;351(15):1513-20
15470214
J Clin Oncol. 1999 Nov;17(11):3461-7
10550143
Cell Cycle. 2005 Apr;4(4):549-51
15738652
Cancer Res. 1987 Jul 15;47(14):3688-91
2439196
J Biol Chem. 1999 Dec 3;274(49):34940-7
10574969
Exp Cell Res. 1988 Jul;177(1):122-31
3134246
J Biol Chem. 1997 Aug 29;272(35):22199-206
9268365
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5
9618505
Jpn J Cancer Res. 1992 Apr;83(4):324-8
1506265
Cancer Res. 2006 Jul 15;66(14):7237-44
16849572
Nat Genet. 1999 Jan;21(1):103-7
9916800
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4
7937876
Nat Med. 1995 Jul;1(7):686-92
7585152
Cancer Res. 1997 Sep 1;57(17):3697-707
9288776
J Antibiot (Tokyo). 1990 Dec;43(12):1524-32
2276972
Cancer Res. 1995 Oct 15;55(20):4525-30
7553621
Trends Pharmacol Sci. 1994 Jul;15(7):233-8
7940985
Exp Cell Res. 1994 Sep;214(1):189-97
8082721
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
Cancer Res. 1996 Feb 15;56(4):722-7
8631003
J Clin Oncol. 2008 Mar 1;26(7):1148-59
18309951